ライフサイエンスコーパス: liposomal

1 The liposomal 5(6)-carboxy-DCFH2 can be targeted to other ti

2 ed from knees of rats with PTOA treated with liposomal A2AR agonist revealed downregulation of genes

3 improved after intraarticular injections of liposomal A2AR agonist.

4 Liposomal accumulation in tumors and organs was followed

5 tumor development in patients, showed higher liposomal accumulation than slow-growing xenografts.

6 Furthermore, a liposomal adjuvant with QS21 and a TLR4 agonist (GLA-LSQ

7 accine Ag doses with a novel potent cationic liposomal adjuvant, cationic adjuvant formulation 09, co

8 iposomes, secondary binding may also lead to liposomal aggregation as detected by dynamic light-scatt

9 Liposomal ALD (L-ALD) has been suggested as a suitable a

10 wn in both in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise cancer cells

11 Importantly however, liposomal alendronic acid proved markedly superior compa

12 njected into the peritoneal cavity, free and liposomal alendronic acid were both highly effective as

13 , we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-ref

14 ogical resolution after course of parenteral Liposomal Amphotercin B.

15 ter, along with IV caspofungin (50 mg/d) and liposomal amphotericin B (300 mg/d).

16 reated with 30 mg/kg body weight intravenous liposomal amphotericin B (AmBisome) divided as 6 equal d

17 activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococc

18 ty and efficacy of combination therapy using liposomal amphotericin B (LAmB) and MIL for treating PKD

19 ed safety profile and antifungal efficacy of liposomal amphotericin B (LAmB) compared to conventional

20 Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an impor

21 tolerability of high-dose weekly (10 mg/kg) liposomal amphotericin B (LamB) for antifungal prophylax

22 Liposomal amphotericin B and MIL combination for treatin

23 amined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individual

24 We have evaluated liposomal amphotericin B in 20 patients with DL in an op

25 Liposomal amphotericin B is an effective therapy for DL,

26 First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while

27 Although liposomal amphotericin B was considered well tolerated,

28 Liposomal amphotericin B was started within a median of

29 phigus foliaceus died despite treatment with liposomal amphotericin B, 3 mg/kg/d, and a young girl wi

30 antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be mu

31 sed antimicrobials (meropenem, piperacillin, liposomal amphotericin B, caspofungin, and voriconazole)

32 center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant

33 hen prospectively screened twice a week, and liposomal amphotericin-B therapy initiated based on a po

34 B) for protein detection, which integrates a liposomal amplifier and sandwich immunoassay format with

35 Liposomal and cellular transport activity of the squaram

36 ficacy in patients was not different between liposomal and conventional chemotherapy as assessed by o

37 We tested both liposomal and emulsion based CAFs with solid and fluid p

38 Novel carriers include liposomal and polymeric nanoparticles, wafers, microchip

39 ith advanced-stage (T1) KS receive cART plus liposomal anthracycline chemotherapy.

40 Using a targeted liposomal approach, we were able to increase AZ7379 avai

41 findings have translational implications for liposomal approaches as well as for Apo2L/TRAIL and othe

42 We have demonstrated that a liposomal array of well-ordered trimers enhances B cell

43 investigated the immunomodulatory role of a liposomal AZM formulation (L-AZM) in a clinically releva

44 establish the immunomodulatory properties of liposomal AZM formulations.

45 Liposomal batches were characterized and compared for th

46 3004, a lipidated TLR7/8 agonist, within the liposomal bilayer in order to achieve co-delivery, allow

47 LR4 and lipidated TLR7/8 agonists within the liposomal bilayer leads to innate and adaptive immune sy

48 The osmotic pressure across the liposomal bilayer was varied to induce shape deformation

49 n this study, we describe the development of liposomal bortezomib nanoparticles, which was accomplish

50 -1-targeted multi-drug and even non-targeted liposomal BTZ formulations for the enhancement of patien

51 who received postprocedural intrapericardial liposomal bupivacaine (LB)+oral colchicine (LB group) an

52 gery compared with those who did not receive liposomal bupivacaine (mean [SD] age, 64.9 [8.4] years;

53 Among 199 patients, those who received liposomal bupivacaine after primary TKA (mean [SD] age,

54 Drug utilization evaluation of liposomal bupivacaine for local infiltration in TKA.

55 3, 2014-March 2, 2015) the implementation of liposomal bupivacaine for local infiltration in TKA.

56 [3.0-7.5]; P = .001), patients who received liposomal bupivacaine had greater median (interquartile

57 Despite the widespread use of liposomal bupivacaine in transversus abdominis plane blo

58 Liposomal bupivacaine is a novel extended-duration anest

59 Athough liposomal bupivacaine is widely used, it is unknown if t

60 ractice: the effect of local infiltration of liposomal bupivacaine on perioperative outcomes in patie

61 We hypothesized that liposomal bupivacaine plane block would result in decrea

62 Local infiltration of liposomal bupivacaine reduces use of opioids in the firs

63 e are no apparent clinical benefits to using liposomal bupivacaine transversus abdominis plane block

64 nesthesia care unit among those who received liposomal bupivacaine vs those who did not (4 vs 20; P =

65 it were improved among patients who received liposomal bupivacaine vs those who did not (4.0 [0.0-6.6

66 o pain was improved among those who received liposomal bupivacaine vs those who did not (44 vs 19; P

67 was also reduced among patients who received liposomal bupivacaine vs those who did not (49 vs 91; P

68 sured by morphine milligram equivalents when liposomal bupivacaine was compared to simple bupivacaine

69 cluded in the analysis, 57 patients received liposomal bupivacaine, 55 patients received simple bupiv

70 ormed transversus abdominis plane block with liposomal bupivacaine, simple bupivacaine, or normal sal

71 after surgery than those who did not receive liposomal bupivacaine.

72 ultrasound is used as a stimulus to liberate liposomal calcium ions, which then trigger the enzymatic

73 Finally, liposomal carfilzomib demonstrated enhanced synergy in c

74 tudy establishes the successful synthesis of liposomal carfilzomib nanoparticles that demonstrates im

75 Here, we report the engineering of liposomal carfilzomib nanoparticles to overcome these pr

76 Liposomal carfilzomib nanoparticles were efficiently tak

77 ogenicity-based investigation with candidate liposomal carriers was conducted.

78 nticity of the strong CD8(+) T-cell inducing liposomal cationic adjuvant formulation 09 (CAF09), whic

79 clude that simple analytical measurements of liposomal changes in lipid packaging, permeability, and

80 were synthesized to prepare transition metal liposomal chemical exchange saturation transfer (lipoCES

81 The efficient delivery of liposomal chemotherapeutics relies, however, on the enha

82 Liposomal chemotherapy offers several advantages over co

83 estigated the safety and efficacy of inhaled liposomal ciprofloxacin (ARD-3150) in two phase 3 trials

84 al schistosomiasis with macrophage-depleting liposomal clodronate (LC) to define how macrophages medi

85 rophages in the bladder by administration of liposomal clodronate led to higher UPEC burdens.

86 We found that liposomal clodronate pretreatment of C57BL/6 mice permit

87 ctomy or depletion of splenic macrophages by liposomal clodronate protects against PIFA-induced chemo

88 Macrophage depletion by liposomal clodronate resulted in a reversal of the benef

89 Use of liposomal clodronate to deplete resident AMs (rAMs) resu

90 Mice were treated with liposomal clodronate to investigate the effect of macrop

91 by depletion of monocytes or macrophages by liposomal clodronate treatment or genetic deficiency of

92 anced by pre-treatment of the recipient with liposomal clodronate, a macrophage depleting agent, with

93 At day 30, liposomal clodronate-mediated macrophage depletion reduc

94 Liposomal clodronate-mediated macrophage depletion signi

95 Thus, liposomal co-encapsulation may be a useful and flexible

96 Liposomal codelivery of tumor antigen and Toll-like rece

97 trolled by external signals as well as inter-liposomal communication without crosstalk.

98 Alternatively, cationic liposomal components or polymers can be used to encapsul

99 Delivery of the liposomal constructs and cell destruction correlated wel

100 These particles consist of 30 nm liposomal cores, composed of an FDA-approved 1,2-dioleoy

101 Future clinical trials should assess liposomal cyclosporine in larger study populations.

102 rgeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therap

103 s of rituximab and four doses of intrathecal liposomal cytarabine.

104 inical trials directly comparing efficacy of liposomal cytotoxic chemotherapy versus their equivalent

105 e model and predict API suitability for nano-liposomal delivery by fixing the main experimental condi

106 Furthermore, liposomal delivery of a metabolically resistant 5-InsP(7

107 s also rescued in a dose-dependent manner by liposomal delivery of a metabolically resistant methylen

108 oration of endothelial Foxm1 expression, via liposomal delivery of Foxm1 plasmid DNA to Hif1a(f/f)/Ti

109 IG-I/MAVS pathway is stimulated, such as via liposomal delivery of poly(I:C).

110 Liposomal delivery of prednisolone improved renal bio-av

111 We have developed a liposomal delivery system for a prodrug of vinblastine (

112 his study, we designed a dual functionalized liposomal delivery system, surface modified with transfe

113 preventing the development of fibrosis after liposomal depletion of circulating monocytes.

114 evaluated the influence of the EPR effect on liposomal distribution in vivo by injection of pegylated

115 us carboplatin (AUC 5, day 1) plus pegylated liposomal doxorubicin (30 mg/m(2), day 1) every 4 weeks,

116 igned a fibronectin-targeting CREKA-modified liposomal doxorubicin (CREKA-Lipo-Dox) for the therapy o

117 herapeutic outcomes than clinically approved liposomal doxorubicin (Doxil) in HER2-overexpressing BT4

118 Studies have shown that liposomal doxorubicin (Lipo-DOX), a chemotherapy agent w

119 itors, doxorubicin, etoposide, and pegylated liposomal doxorubicin (PLD) in vivo, utilizing ovarian c

120 Since pegylated liposomal doxorubicin (PLD) was the most prevalent formu

121 r photodynamic damage, resulting in enhanced liposomal doxorubicin accumulation in tumors.

122 amycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with a

123 in tumors treated with temperature-sensitive liposomal doxorubicin and ultrasound hyperthermia.

124 taining regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizumab.

125 s formulation than clinically representative liposomal doxorubicin for breast cancer treatment and pr

126 free doxorubicin and was superior to that of liposomal doxorubicin formulations.

127 oxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to fre

128 eport rationally engineered peptide-targeted liposomal doxorubicin nanoparticles that have an enhance

129 vanced-stage KS, chemotherapy with pegylated liposomal doxorubicin or paclitaxel is the most common t

130 technique is able to identify both free and liposomal doxorubicin throughout the spheroid after just

131 ermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the brain.

132 acizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE)

133 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DA

134 Liposomal doxorubicin, bevacizumab, and the mTOR inhibit

135 Spheroids were dosed with liposomal doxorubicin, free doxorubicin, or media contro

136 vestigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or topotecan),

137 ly assigned to receive carboplatin-pegylated liposomal doxorubicin-bevacizumab (experimental group) a

138 Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new standard trea

139 n-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin.

140 (PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots).

141 e MALDI-IMS to analyze drug penetration of a liposomal drug carrier as well as its metabolites.

142 bility to both small dye molecules and large liposomal drug carriers were quantified using fluorescen

143 rstanding is required to optimize and design liposomal drug delivery systems capable of controllable

144 Nanomedicine, particularly liposomal drug delivery, has expanded considerably over

145 se to identify novel candidate molecules for liposomal drug delivery.

146 ical activities, may be the basis for future liposomal drug development.

147 current challenges in peptide-functionalized liposomal drug formulation.

148 AF4) to accurately and reproducibly separate liposomal drug formulations into their component populat

149 nique may prove useful for rapid analysis of liposomal drug formulations or rapid, robust, direct mea

150 y, by supplementing ablation with concurrent liposomal drug therapy, a complete and durable response

151 rably over the past few decades, and several liposomal drugs are already providing improved clinical

152 inical and commercial success of a number of liposomal drugs, each of which required a tailored formu

153 dels for the computer-model-driven design of liposomal drugs.

154 atechin or free green tea extract (GTE), and liposomal encapsulated catechin or liposomal encapsulate

155 GTE), and liposomal encapsulated catechin or liposomal encapsulated GTE.

156 ection model was used to investigate whether liposomal-encapsulated prednisolone (LP) facilitates loc

157 We measured liposomal encapsulation and cellular uptake of the monod

158 With liposomal encapsulation of each drug pair, we enabled un

159 Liposomal encapsulation resulted in a circulation half-l

160 lexes with the explicit aim of demonstrating liposomal encapsulation, bioavailability in cultured neu

161 apsulation method to nucleobase analogues, a liposomal entrapment method once conceived useful only f

162 Cl(-) flux process with the use of different liposomal fluorescence assays, and supported by addition

163 ally confirmed using reconstituted MscL in a liposomal fluorescent efflux assay.

164 Doxorubicin (Dox) is approved for use in liposomal form for the treatment of ovarian cancer.

165 mers administered in soluble or high-density liposomal formats.

166 Among them, compound 29d encapsulated in a liposomal formulation (e.g., 29dL) significantly suppres

167 at the passive delivery of an edge-activated liposomal formulation can effectively carry siRNA throug

168 Using a singular liposomal formulation for CPT, we describe a semi-mechan

169 The liposomal formulation in cancer drug delivery can be fac

170 We demonstrate that the liposomal formulation of AZM enhances the drug's efficac

171 Topical liposomal formulation of cyclosporine, 2.0% w/w, is effe

172 sdegib to target the hedgehog pathway, and a liposomal formulation of daunorubicin and cytarabine (CP

173 cin, non-crosslinked Rososome and commercial liposomal formulation of doxorubicin (DOXIL).

174 in, we report a novel radioprotector drug, a liposomal formulation of gamma-tocotrienol (GT3), or GT3

175 e verified experimentally and PEGylated nano-liposomal formulation of mupirocin (Nano-mupirocin) was

176 Doxil, a liposomal formulation of the chemotherapeutic drug doxor

177 of these specific macrophages, we designed a liposomal formulation of vancomycin that is efficiently

178 Liposomal formulation prevents undesirable side effects

179 on recent advances in peptide-functionalized liposomal formulation techniques in cancer diagnosis and

180 so will highlight different aspects of novel liposomal formulation techniques that incorporate surfac

181 TPT may benefit from liposomal formulation using active loading strategies to

182 the circulation after the administration of liposomal formulation was characterized by prolonged cir

183 This liposomal formulation was developed to improve the toler

184 The liposomal formulation was loaded with peptide, human epi

185 The optimized diaCEST liposomal formulation with a BA-to-lipid ratio of 25% ex

186 adjuvant in stable emulsion (GLA-SE) or in a liposomal formulation with QS21 (GLA-LSQ).

187 other linkers to achieve surface adsorption, liposomal formulation, and encapsulating nanoparticles a

188 did not show any efficacy advantage for the liposomal formulation.

189 Liposomal formulations for the treatment of cancer and o

190 to monitor TPT release from actively loaded liposomal formulations having a low intravesicular pH.

191 ns, with the largest class of products being liposomal formulations intended for cancer treatments.

192 Temperature-sensitive liposomal formulations of chemotherapeutics, such as dox

193 Liposomal formulations of N-BP have been proposed to imp

194 ty and performance seen with actively-loaded liposomal formulations of TPT and other weakly-basic ant

195 Liposomal formulations of VE analogues especially of alp

196 Present achievements in: (i) preparation of liposomal formulations of VE analogues, (ii) physico-che

197 ture and the imminent arrival of theranostic liposomal formulations to move this field forward.

198 Resulting liposomal formulations were found to preserve the origin

199 Within this work, a range of liposomal formulations were investigated to develop a li

200 Various liposomal formulations were tested: conventional liposom

201 enicity in both free (micellar) state and in liposomal formulations when tested in rabbits in vivo (s

202 ty and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed

203 Through comparisons to liposomal formulations, which have been studied extensiv

204 ling during UF; and (3) preozonation reduces liposomal fouling during UF, likely due to the disruptio

205 We hypothesize that liposomal fusion of 15-epi-LXA4 (Lipo-15-epi-LXA4) or fr

206 The trans-placental permeability of liposomal Gadolinium (Gd) nanoparticle contrast agents w

207 nced MRI using a long circulating blood-pool liposomal gadolinium contrast agent that does not penetr

208 ectably low transplacental permeation of the liposomal Gd agent, while the clinical agent (Multihance

209 enate dimeglumine), and a novel experimental liposomal Gd agent.

210 determine both maternal and fetal safety of liposomal Gd is suggested.

211 creased tumor uptake of both gemcitabine and liposomal gemcitabine and significantly improved anti-tu

212 ive tumor model of murine pancreatic cancer, liposomal gemcitabine combined with local hyperthermia i

213 A limitation of liposomal gemcitabine has been the low loading efficienc

214 ignificantly improved anti-tumor efficacy of liposomal gemcitabine.

215 ation in dLNs compared with a combination of liposomal HIV gp41 and soluble CDN.

216 A combination of a poorly immunogenic liposomal HIV gp41 peptide antigen and NP-cdGMP robustly

217 ed membrane permeabilization is enabled with liposomal inclusion of 10 molar % porphyrin-phospholipid

218 able, focusing on this new generation of non-liposomal L-NVs and showing their similarities and diffe

219 field of L-NV design and synthesis, and non-liposomal L-NVs have been recently developed; this new g

220 old nanoparticles that are encapsulated in a liposomal (Lip) system that can produce H2 gas in situ u

221 are taken up, their CE core is hydrolyzed by liposomal lipases to generate free cholesterol (FC).

222 dithiol (1KDa), a free radical initiator and liposomal lipids at the liposome formation step.

223 irradiation at 730 nm led to peroxidation of liposomal lipids, allowing drug release.

224 formulations were investigated to develop a liposomal lymphatic targeting system.

225 dies, we describe ADx-001, an Abeta-targeted liposomal macrocyclic gadolinium (Gd) imaging agent, for

226 Liposomal-mediated delivery of N-MYLK mutant but not Del

227 duced by mechanically induced defects in the liposomal membrane caused by the oscillation of the iron

228 ed that over 90% of tPA was released through liposomal membrane destabilization involving membrane fu

229 uncontrolled passive permeability across the liposomal membrane or upon fusion with other membranes.

230 cell-penetrating peptide-modified fusogenic liposomal membrane was coated on the core, which had an

231 However, when the phospholipids within the liposomal membrane were hydrolyzed by PLA2, encapsulated

232 The interaction of liposomal membranes composed of soybean phosphatidylchol

233 ed Bcl2 interacting protein) in assays using liposomal membranes.

234 de anion and sodium cation transport in both liposomal models and cells, and promote cell death by in

235 enhance the transport of chloride anions in liposomal models and promote sodium chloride influx into

236 High-throughput sequencing, liposomal nanoallergen display, bead-based assays, and p

237 Development of liposomal nanomedicine with robust stability, high drug

238 ely and support the rapid translation of new liposomal nanomedicines from bench to bedside, new cost-

239 understanding and optimizing the effects of liposomal nanoparticle design parameters for enhancement

240 It is a liposomal nanoparticle loaded with a synthetic mimic of

241 , recent reports show that certain pegylated liposomal nanoparticles (PLNs) and polymeric nanoparticl

242 Liposomal nanoparticles are the most commonly used drug

243 Here, we demonstrated that liposomal nanoparticles bearing an allergen and a high-a

244 combination with a near-infrared dye, these liposomal nanoparticles can serve as bimodal PET/optical

245 Liposomal nanoparticles modified with 0.25 mol% of a sho

246 rategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Si

247 f liposomes to yield stable and reproducible liposomal nanoparticles.

248 The liposomal nanoprobe PGN-L-IO/DiR was fully characterized

249 The mean particle size of liposomal nanovesicles containing PF30 was found to be i

250 ical utilization feasibility of niosomal and liposomal nanovesicles loading Isoleucine-Proline-Prolin

251 acting proteins with PI5P-tagged fluorescent liposomal nanovesicles.

252 cal properties during long-term storage than liposomal one.

253 Rs or MHC class II molecules on B cells, the liposomal particles also elicited IgM, IgG1, IgG2b, and

254 emained limited due to the slow diffusion of liposomal particles within the tumor and limited release

255 his process, we have synthesized a series of liposomal particles, similar to the size of viruses, tha

256 , (ii) development of PEGylated and targeted liposomal PAs, (iii) physico-chemical characterization o

257 ed activation of semiconductors for advanced liposomal PEC bioanalysis.

258 C-3 cell line, and binding was observed with liposomal peptide concentrations as low as 0.16mol%.

259 Liposomal photoelectrochemical (PEC) bioanalysis holds e

260 ntaining luciferase reporter gene) to form a liposomal-plasmid DNA (LpDNA) complex.

261 After that, spray dried liposomal powders containing BME were added to chocolate

262 ared to spray dried extract, chitosan coated liposomal powders provided better protection of anthocya

263 AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine.

264 The co-loaded liposomal preparation was also targeted to the transferr

265 A novel liposomal preparation was developed, co-loaded with NCL-

266 dose of 50 mg taxane/kg, ephrin A2-targeted liposomal prodrug showed greater antitumor activity than

267 show both positive or negative chemotaxis of liposomal protocells.

268 nged the biodistribution compared to the non-liposomal radiopeptide in vivo, although interestingly t

269 fluorescence method was developed to monitor liposomal release kinetics of the anticancer agent topot

270 ese findings, the developed model describing liposomal release of TPT may be used in the future to ev

271 A major challenge in liposomal research is to minimize the leakage of encapsu

272 Atu027 is a novel liposomal RNA interference therapeutic that includes a s

273 or far weaker in intensity in the spectra of liposomal sample containing ciprofloxacin nanocrystals.

274 ed GGPP supply via GGPS11, presumably due to liposomal sequestration.

275 nt study, an electrochemical method based on liposomal signal amplification platform is proposed for

276 t inhibition of angiopoietin-2 expression by liposomal siRNA in vivo improved absolute survival by 50

277 ynthesis and evaluation of immunotherapeutic liposomal spherical nucleic acids (SNAs) for TNBC therap

278 prised of spherically-arrayed antisense DNA (liposomal spherical nucleic acids [L-SNAs]), which are a

279 Recently developed liposomal spherical nucleic acids overcome this barrier

280 This composition was shown to increase liposomal stability, prolong the circulation half-life,

281 Vesosomes are nested liposomal structures with high potential as advanced dru

282 erest for stabilization/functionalization of liposomal surfaces as well as detection of polyvalent mo

283 replacement by intra-articular injection of liposomal suspensions containing adenosine prevents deve

284 ostasis and here we report that injection of liposomal suspensions of either adenosine or a selective

285 Herein, we report a multifunctional liposomal system (164.6 +/- 5.3 nm in diameter) which ca

286 An efficient liposomal system for screening the zinc ionophore activi

287 transmembrane proteins reconstituted into a liposomal system.

288 ed to investigate the antifungal activity of liposomal systems containing Spirulina sp. LEB-18 phenol

289 The features of this ultra-sensitive liposomal TIRF-FOB are (i) fluorescence is excited via e

290 d optimize loading and subsequent release of liposomal TPT formulations utilizing active loading stra

291 n against Cu(2+)-mediated degradation of the liposomal unsaturated fatty acids).

292 However, liposomal uptake was significantly correlated with tumor

293 ns could be made regarding the EPR effect or liposomal uptake.

294 pH-sensitive liposomal vaccine administration elevated IgG2c/IgG1 ant

295 Here, we describe a liposomal vaccine carrier that delivers tumor antigens t

296 l administration of vancomycin (particularly liposomal vancomycin with optimized intracellular penetr

297 The anti-cancer effect of these liposomal VE analogues has been successfully demonstrate

298 Liposomal vincristine is also approved for relapsed dise

299 for detailed analysis of fusion kinetics for liposomal, viral, and cellular fusion processes; however

300 been suggested as a suitable alternative to liposomal ZOL (L-ZOL), due to unexpected mice death expe